Skip to main navigation
Close
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Blog
Mar 11, 2019
| Anna McDermott-Vitak
Talking Female Leadership at Access! 2019
Press Release
Mar 7, 2019
| Rachel Schwartz
AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements
Press Release
Mar 5, 2019
| Rachel Schwartz
AAM Statement on Dr. Scott Gottlieb's Departure
Press Release
Feb 28, 2019
| Rachel Schwartz
New Study Shows Seniors Paid Nearly $22 Billion in Extra Out-of-Pocket Costs for Generic Medicines
Blog
Feb 26, 2019
| Erica Klinger
Rich’s Generic Story: No Sweat
Press Release
Feb 25, 2019
| Rachel Schwartz
Jonathan Kimball Joins AAM as Vice President, Trade and International Affairs
Blog
Feb 20, 2019
| Craig Burton
HHS Proposal Will Help America’s Patients Realize the Full Value of Their Generics and Biosimilars
Press Release
Feb 19, 2019
| Rachel Schwartz
Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631
Blog
Feb 15, 2019
| Rachel Schwartz
Access! New Orleans Style: An Industry Steps Up
Press Release
Feb 13, 2019
| Rachel Schwartz
AAM Welcomes Re-Introduction of the PACED Act
Press Release
Feb 8, 2019
| Rachel Schwartz
Statement from the Association for Accessible Medicines on the Introduction of the CREATES Act
Fact Sheet
Feb 7, 2019
| Erica Klinger
Opioid Tax Bills
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2024
GRx+Biosims 2023
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action